Continuing Medical Education (CME) Programs

Topics discussed during this program include:

• The impact of moderate-to-severe asthma on airway remodeling and lung development in children
• Conditions that occur frequently with asthma 
• Strategies to develop personalized asthma treatment plans 

Please note AMA PRA Category 1 Credit™ is no longer available.

Watch on YouTube

Topics discussed during this program include:

• The burden of uncontrolled asthma
• The impact of asthma phenotypes/endotypes and type 2 comorbidities
• Current data on the efficacy and safety of biologics

Please note the AMA PRA Category 1 Credit™ is no longer available.

Watch on YouTube

Topics discussed during this program include:

• Roles of various inflammatory pathways in severe asthma
• Mechanisms of action of various therapies and their safety and efficacy data
• How a new treatment option targeting TSLP can be integrated into asthma management plan

Please note AMA PRA Category 1 Credit™ is no longer available.

Watch on YouTube

Topics discussed during this program include:

• The effects of comorbid conditions on asthma
• The evidence behind biologic treatments for asthma
• Strategies to recognize and better manage moderate-to-severe asthma

Earn AMA PRA Category 1 Credit™ through March 5, 2025. Watch on demand.

Topics discussed during this program include:

• Strategies to enhance access to individualized care among people of racial and ethnic minorities
• How to identify patients with moderate-to-severe asthma who may benefit from targeted biologic agents
• How to identify the place of type-2-targeted biologics in the management of moderate-to-severe asthma

Please note AMA PRA Category 1 Credit™ is no longer available.

Watch on YouTube

Topics discussed during this program include:

• The changing landscape of food allergy management
• Newer approaches to enhance food allergen tolerance
• The key roles of patients and their families when making therapeutic decisions 

Please note AMA PRA Category 1 Credit™ is no longer available. There are two sessions in this program.

Session 1

Watch on YouTube

Session 2

Watch on YouTube

Topics discussed during this program include:

• The diagnostic process for food allergies
• Emerging biologics targeting IgE
• The role of shared decision-making in food allergy management

Earn AMA PRA Category 1 Credit™ through March 1, 2025. Watch on demand.

Topics covered during this program include:

• Current evidence for currently approved agents for the treatment of moderate-to-severe atopic dermatitis (AD)
• How the presence of comorbidities can influence the treatment of moderate-to-severe AD
• How to help patients reach long-term control of their disease

Please note AMA PRA Category 1 Credit™ is no longer available.

Watch on YouTube

Topics covered during this program include:

• Guideline recommendations for the management of moderate-to-severe atopic dermatitis (AD) in infants and young children
• Efficacy and safety data from recent studies on treatments
• The effects of newer treatments for AD on patient outcomes

Earn AMA PRA Category 1 Credit™ through August 21, 2025. Watch on demand.

Topics covered during this program include:

• The impacts that age, race, and ethnicity have on atopic dermatitis (AD)
• Management of moderate-to-severe atopic dermatitis
• The unique challenges that people from diverse racial and ethnic group face when attempting to access care

Please note AMA PRA Category 1 Credit™ is no longer available.

Watch on YouTube

Topics covered during this program include:

• Alignment of therapeutic decisions to clinical endophenotypes in patients of different age groups and races
• Evidence-based treatment recommendations to achieve long-term disease control
• Strategies to encourage shared-decision-making with patients

Please note AMA PRA Category 1 Credit™ is no longer available. There are four modules in this program.

Module 1

Watch on YouTube

Module 2

Watch on YouTube

Module 3

Watch on YouTube

Module 4

Watch on YouTube

Topics covered during this program include:

• Practical tips on assessing disease severity
• Treatment strategies and managing side effects
• Challenging case studies of hand and foot atopic dermatitis
• Efficacy and safety data from recent studies on treatments
• The effects of newer treatments for AD on patient outcomes

Earn AMA PRA Category 1 Credit™ through October 18, 2025. Watch on demand.

Topics discussed during this program include:

• Guidance on EoE diagnosis
• The Importance of asking questions to uncover adaptive behaviors
• Details of the current treatment paradigm

Please note AMA PRA Category 1 Credit™ is no longer available.

Watch on YouTube

Topics covered during this program include:

• The symptoms of eosinophilic esophagitis (EoE) in babies and young children
• Safety and efficacy data from clinical trials of newly approved agents for EoE in babies and young children
• Strategies to counsel children with EoE and their caregivers on best practices for care transitions as children reach adolescence and adulthood

Earn AMA PRA Category 1 Credit™ through Nov. 21, 2025. Watch on demand.

Topics covered during this program include:

• The underlying pathophysiology of EoE and non-EoE eosinophilic gastrointestinal diseases (EGIDS)
• Safety and efficacy data with current and emerging therapies of EoE
• The current evidence on the efficacy and safety data of emerging biologics for non-EoE EGIDs

Earn AMA PRA Category 1 Credit™ through Dec. 12, 2025. Watch on demand.

Topics discussed during this program include:

• How to recognize the symptoms of eosinophilic esophagitis (EoE) across a variety of patient ages to facilitate an early diagnosis
• Emerging data on new, more efficient, targeted agents for the management of EoE

Please note AMA PRA Category 1 Credit™ is no longer available.

Watch on YouTube

Topics covered during this program include:

• The latest understanding of chronic rhinosinusitis with nasal polyps (CRSwNP), or nasal polyps
• People at high risk for recurrence of nasal polyps
• Treatment options for people with nasal polyps

Please note AMA PRA Category 1 Credit™ is no longer available. There are four modules in this program.

Module 1

Watch on YouTube

Module 2

Watch on YouTube

Module 3

Watch on YouTube

Module 4

Watch on YouTube

Topics covered during this program include:

• Cases illustrating the adoption of biologics as a therapeutic option for nasal polyps  
• The underlying pathophysiology of nasal polyps driven by type 2 inflammation 
• Strategies for implementing interdisciplinary collaborative care 

Please note AMA PRA Category 1 Credit™ is no longer available.

Watch on YouTube

Topics covered during this program include:

• Patient factors to predict relapse risk and determine candidacy for biologics
• Emerging models for interdisciplinary collaboration in the care of people with nasal polyps

Please note AMA PRA Category 1 Credit™ is no longer available.

Watch on YouTube

Topics covered during this program include:

• Strategies to improve olfactory dysfunction in chronic rhinosinusitis with nasal polyps (CRSwNP)
• Applying evidence-based guidelines on CRSwNP and managing comorbidities to treat the patient as a whole
• Long-term efficacy data for biologic therapy from real-world studies in the treatment of nasal polyps

Earn AMA PRA Category 1 Credit™ through August 25, 2025. Watch on demand.

Topics covered during this program include:

• The mechanism behind olfactory dysfunction in patients with chronic rhinosinusitis with nasal polyps (CRSwNP)
• Tools and strategies to evaluate olfactory function in patients with CRSwNP
• The burden of CRSwNP on patients

Earn AMA PRA Category 1 Credit™ through Nov. 20, 2025. Watch on demand.

Topics discussed during this course include:

• The patient burden of nasal polyps
• Limitations of traditional nasal polyp treatments and emerging therapies for those with nasal polyps
• Rationale for targeted approaches to nasal polyp management

Please note AMA PRA Category 1 Credit™ is no longer available.

Watch on YouTube

Topics discussed during this program include:

• Patient-centered treatment options for chronic rhinosinusitis with nasal polyps (CRSwNP)
• Disease burden
• The impacts that biologics and surgery have on symptoms and quality of life (QoL)

Please note AMA PRA Category 1 Credit™ is no longer available.

Watch on YouTube

Topics discussed during this program include:

• The underlying pathways that lead to nasal polyps and drive recurrent disease and treatment resistance
• The burdens faced by patients with nasal polyps
• Evidence supporting the efficacy and safety of biologic agents for the treatment of nasal polyps

Please note AMA PRA Category 1 Credit™ is no longer available.

Watch on YouTube

Topics covered during this program include:

• The criteria for the candidacy of biologic therapy for chronic rhinosinusitis with nasal polyps (CRSwNP) in the EPOS/EUFOREA guidelines
• The place of biologic therapy in current treatment guidelines
• The relative impact of various treatment in improving olfaction and other patient-valued parameters.

Earn AMA PRA Category 1 Credit™ through Nov. 12, 2025. Watch on demand.

Topics discussed during this program include:

• The relationships between chronic inducible urticaria (CIndU) triggers and underlying pathophysiologic pathways
• How to optimize treatment of chronic spontaneous urticaria (CSU) and CIndU
• Strategies to identify urticaria subtypes

Please note AMA PRA Category 1 Credit™ is no longer available.

Watch on YouTube

Topics discussed during this program include:

• The latest in chronic spontaneous urticaria (CSU) treatment options
• Management and treatment escalation standards
• Perspectives from the patient journey

Please note AMA PRA Category 1 Credit™ is no longer available.

Watch on YouTube